Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis.
Jonathan N PrianttiNatasha Maranhão Vieira RodriguesFrancisco Cezar Aquino de MoraesAllyson Guimarães CostaDeborah Laredo JeziniMaria Izabel Ovellar HeckmannPublished in: Endocrine (2024)
ATC patients, especially in the neoadjuvant setting, with a tolerable safety profile. However, further clinical trials are warranted to investigate these findings.